

Table S1. Sensitivity analysis around the input parameters for sensitivity of CA125 (first line screen) and TVS (second line screen)

				89% 1 yr prior to diagnosis, base case otherwise	89% 1 yr prior to diagnosis, base case otherwise	95% CI Lower Bound of Base Case	95% CI Upper Bound of Base Case
CA125 Sensitivity	-	Base Case	Base Case				
TVS Sensitivity	-	63%	85%	63%	85%	63%	63%
EFFECTIVENESS							
Stage at diagnosis							
I	18%	34%	38%	37%	42%	26%	47%
II	11%	13%	13%	14%	14%	13%	14%
III	32%	30%	28%	30%	29%	31%	25%
IV	39%	23%	20%	19%	15%	30%	15%
Stage shifts (late to early)	N/A	17%	21%	20%	26%	9%	30%
Total Mortality Reduction	N/A	13%	15%	15%	17%	8%	20%
Due to early detection of malignancy in cases	N/A	10%	12%	12%	14%	5%	17%
Due to laparoscopy in cases prior to the onset of malignancy	N/A	3%	3%	3%	3%	3%	3%
Lead time (per screen detected case)	N/A	0.97	0.97	0.86	0.85	0.86	1.32
YLS (per screen detected case)	N/A	1.68	1.61	1.5	1.45	1.76	1.98
COST							
Cost-effectiveness	N/A	\$88,993	\$74,228	\$76,966	\$62,911	\$147,996	\$52,804
Total cost (millions)	\$865	\$1,741	\$1,743	\$1,744	\$1,748	\$1,735	\$1,756
Screening test cost (total)	\$0	\$742	\$742	\$742	\$742	\$742	\$742
Laparoscopy cost (FP: healthy women)	\$0	\$128	\$128	\$128	\$128	\$128	\$128
Laparoscopy cost (FP: benign disease)	\$81	\$84	\$84	\$84	\$84	\$87	\$85
Cancer treatment cost (TP)	\$784	\$787	\$789	\$790	\$794	\$779	\$802